Tang-Jia Medical Refiles for Hong Kong IPO to Fund Metabolic Disease Devices

Hangzhou Tang-Jia Medical Technology Co., Ltd., a medical device company focused on metabolic diseases, has renewed its bid for a public listing on the Hong Kong Stock Exchange's Main Board. The move signals the company's continued effort to raise capital to advance its product pipeline and commercialization efforts.

The Renewed Application

According to a disclosure from the Hong Kong Stock Exchange (HKEX) on August 28, Tang-Jia Medical has formally submitted its listing application. The filing lists ICBC International and Caitong International as the joint sponsors for the initial public offering.

This marks the company's second attempt to go public in Hong Kong. The prospectus details Tang-Jia Medical's focus on providing innovative solutions for the treatment and comprehensive management of metabolic conditions.

Product Portfolio and Pipeline

Tang-Jia Medical's offerings are centered on non-invasive or minimally invasive medical technologies. The company's prospectus outlines its current product landscape:

Ad

• Core Product: The Gastric Bypass Stent system (GBS), a type of duodenal-jejunal bypass liner (DJBL) device used in endoscopic procedures for obesity. The company is also working to expand the device's approved use for patients with a lower Body Mass Index (BMI).
• Other Approved Products: The company has two other commercialized products and a registered digital health management platform.
• Pipeline: An additional 13 products are currently in the development pipeline.

Strategic Context

The planned IPO aims to secure funding to support the research, development, and eventual market launch of its extensive pipeline. By targeting metabolic diseases, particularly obesity, Tang-Jia Medical is positioning itself in a large and growing healthcare market in China and globally.

For investors, the filing provides an updated look at the company's strategy and progress since its last application. The success of the listing will be a key factor in its ability to scale operations and compete in the innovative medical device sector.